10 March 2020

ASX Announcement

New publication: CXCR4 in fibrosis

MELBOURNE Australia, 10 March 2020: AdAlta Limited (ASX: 1AD), the next generation antibody company using its i-body technology to develop drug candidates against hard to drug targets, advises that a book chapter co-authored by AdAlta Chief Scientific Officer, Prof Michael Foley has recently been published.

The review chapter, titled "Emerging role of CXCR4 in fibrosis", was an invited contribution to *Antifibrotic Drug Discovery*, edited by J Brenneman and M Iyer and published by The Royal Society of Chemistry. The chapter can be sourced via AdAlta's website.[1]

CXCR4 (C-X-C motif chemokine receptor 4) is the G-protein coupled receptor (GPRC) targeted by AdAlta's lead product candidate, AD-214. The chapter briefly describes the role of CXCR4 in many cancers and the wealth of studies indicating that targeting CXCR4 could be an effective therapeutic strategy in fibrotic disease before focussing on the role of CXCR4 in fibrosis of the lung, kidney and eye.

Prof Foley commented, "This review brings together much of the evidence emerging over the past decade implicating CXCR4 in fibrotic disease and validating it as a drug target in fibrosis of the lung (our lead indication for AD-214), eye and kidney (potential additional indications for AD-214). When combined with our recently released data showing that AD-214 binds to CXCR4 for extended periods in monkeys[2] and demonstrates reduces efficacy in the gold standard mouse bleomycin model of Idiopathic Pulmonary Fibrosis (IPF) as measured by reductions in the Ashcroft Score,[3] we have compelling evidence that blocking CXCR4 should modify progression of fibrotic disease, that AD-214 can block CXCR4 *in vivo,* and that it may modify disease progression. As discussed at our recent investor briefing,[4] our next goal is to confirm these findings in humans."

Authorised for lodgement by:

Tim Oldham
CEO and Managing Director
March 2020

[1] http://adalta.com.au/scientific-publications/
[2] http://1ad.live.irmau.com/irm/PDF/1655_0/AD214PKandPDsupportPhaseIweeklydosingobjective
[3] http://1ad.live.irmau.com/irm/PDF/1653_0/AD214effectiveingoldstandardpreclinicalanimalmodel
[4] http://1ad.live.irmau.com/irm/PDF/1657_0/InvestorBriefingStrategicPlan

AdAlta Limited
15/2 Park Drive
Bundoora VIC 3083 Australia

T +61 3 9479 5159
E enquiries@adalta.com.au
ABN 92 120 332 925

adalta.com.au

Notes to Editors
About AdAlta

AdAlta Limited is an Australian-based drug development company headquartered in Melbourne. The Company is using its proprietary technology platform to generate a promising new class of single domain antibody protein therapeutics, known as i-bodies, that have the potential to treat some of today's most challenging medical conditions. The technology mimics the shape and stability of a crucial antigen-binding domain, that was discovered initially in sharks and then developed as a human protein. The result is a range of unique compounds, capable of uniquely interacting with previously difficult to access targets such as G-protein coupled receptors (GPCRs) and ion channels that are implicated in many serious diseases.

AdAlta is currently preparing for its Phase 1 clinical studies for its lead i-body candidate, AD-214. The clinical program is expected to commence in mid-2020 following clinical trial design finalisation and ethics committee approval. AD-214 is being developed for the treatment of Idiopathic Pulmonary Fibrosis (IPF) and other human fibrotic diseases, for which current therapies are sub-optimal and there is a high-unmet medical need. The Company is also in collaborative partnerships to advance the development of its i-body platform. It has an agreement with GE Healthcare for diagnostic imaging agents against several drug targets, including Granzyme B.

AdAlta's strategy is to maximise the products developed using its next generation i-body platform by internally discovering and developing selected i-body enabled product candidates against GPCRs implicated in fibrosis, inflammation and cancer and partnering with other biopharmaceutical companies to develop product candidates against other classes of receptor, in other indications, and in other product formats.

Further information can be found at: www.adalta.com.au

For more information, please contact:

Investors

Tim Oldham, CEO & Managing Director
Tel: +61 403 446 665
E: t.oldham@adalta.com.au

Media

IR Department
Tel: +61 411 364 382
E: gabriella.hold@irdepartment.com.au